✦ LIBER ✦

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

✍ Scribed by Thierry, Alain R; Mouliere, Florent; El Messaoudi, Safia; Mollevi, Caroline; Lopez-Crapez, Evelyne; Rolet, Fanny; Gillet, Brigitte; Gongora, Celine; Dechelotte, Pierre; Robert, Bruno; Del Rio, Maguy; Lamy, Pierre-Jean; Bibeau, Frederic; Nouaille, Michelle; Loriot, Virginie; Jarrousse, Anne-Sophie; Molina, Franck; Mathonnet, Muriel; Pezet, Denis; Ychou, Marc

Book ID: 121662093
Publisher: Nature Publishing Group
Year: 2014
Tongue: English
Weight: 872 KB
Volume: 20
Category: Article
ISSN: 1078-8956
DOI: 10.1038/nm.3511

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical Validation of KRAS, BRAF, and E

Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing

✍ Lin, Ming Tseh (author);Mosier, Stacy L. (author);Thiess, Michele (author);Beier 📂 Article 📅 2014 🏛 American Society of Clinical Pathologists 🌐 English ⚖ 966 KB

Clinical Validation of KRAS, BRAF, and E

Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing

✍ Lin, Ming Tseh (author);Mosier, Stacy L. (author);Thiess, Michele (author);Beier 📂 Article 📅 2014 🏛 American Society of Clinical Pathologists 🌐 English ⚖ 966 KB

Analytical Validation of BRAF Mutation T

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

✍ Aung, Kyaw L.; Donald, Emma; Ellison, Gillian; Bujac, Sarah; Fletcher, Lynn; Can 📂 Article 📅 2014 🏛 American Society for Investigative Pathology 🌐 English ⚖ 422 KB

Quantitative Detection of EGFR Mutations

Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

✍ Taniguchi, K.; Uchida, J.; Nishino, K.; Kumagai, T.; Okuyama, T.; Okami, J.; Hig 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 296 KB

8 The utility of peripheral blood circul

8 The utility of peripheral blood circulating tumour cells for the detection of KRAS, EGFR and BRAF mutations in primary lung cancer

✍ Freidin, M.B.; Mair, D.; Tay, A.; Freydina, D.V.; Chudasama, D.; Popat, S.; Nich 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB

TRAIL receptor upregulation and the impl

TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors

✍ Eftychia Oikonomou; Vivian Kosmidou; Anastasia Katseli; Konstantinos Kothonidis; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 273 KB 👁 2 views

## Abstract TRAIL raises hopes as a promising anti‐tumor agent due to its selectivity toward cancer cells. Higher expression of its pro‐death receptors TRAIL‐R1 (DR4) and TRAIL‐R2 (DR5) attenuates higher sensitivity to TRAIL‐induced apoptosis, and represents a marker for better cancer prognosis and